Pulmonary Hypertension Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with fibrosing mediastinitis (a condition where scar tissue forms in the chest cavity) between November 2024 and November 2026, who are between 18 and 85 years old.
- People who have experienced symptoms of chest tightness, shortness of breath, and reduced ability to exercise.
- People whose chest CT scan showed that enlarged lymph nodes in the chest are pressing on the pulmonary artery, with signs of high blood pressure in the lungs that matches their symptoms.
- People who have signed a consent form before joining the study and are able to follow the study plan, including check-ups over one year.
Who may not be able to join:
- People who currently have an active infection, including infections such as tuberculosis, histoplasmosis, or aspergillosis.
- People whose underlying condition — such as sarcoidosis, Behcet's disease, or a condition called IgG4-related disease — is not currently well controlled.
- People who had a large build-up of fluid around the lungs before treatment.
- People whose breathing tests show lung function is severely reduced, falling below certain thresholds in three specific measures (confirm with trial site for exact values).
- People who have medical reasons why they cannot safely undergo a bronchoscopy (a procedure to look inside the airways) or a procedure to treat blood vessels.
- People who have severe, end-stage failure of another major organ, such as advanced liver disease or late-stage chronic kidney failure.
- People who have a seriously weakened immune system.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 15801511482
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change from Baseline in the Six Minutes Walk Distance at 12 Months.; The incidence of treatment-related serious adverse events (SAE)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.